发布求助
文献互助 智能选刊 最新文献

Expert Opinion on Biological Therapy最新文献

筛选
英文 中文
The future of cancer vaccines against colorectal cancer 抗结直肠癌癌症疫苗的未来
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-04-21 DOI: 10.1080/14712598.2024.2341744
Wenqing Jia, Xiaonan Shen, Zichao Guo, Xi Cheng, Ren Zhao
{"title":"The future of cancer vaccines against colorectal cancer","authors":"Wenqing Jia, Xiaonan Shen, Zichao Guo, Xi Cheng, Ren Zhao","doi":"10.1080/14712598.2024.2341744","DOIUrl":"https://doi.org/10.1080/14712598.2024.2341744","url":null,"abstract":"Colorectal cancer (CRC) is the second most lethal malignancy worldwide. Immune checkpoint inhibitors (ICIs) benefit only 15% of patients with mismatch repair-deficient/microsatellite instability (d...","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140634969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sibeprenlimab, which neutralizes a PRoliferation inducing ligand (APRIL), as a new approach to treating IgA nephropathy 中和 PRoliferation inducing ligand (APRIL) 的 Sibeprenlimab 是治疗 IgA 肾病的新方法
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-04-20 DOI: 10.1080/14712598.2024.2346111
Sheila A Doggrell
{"title":"Sibeprenlimab, which neutralizes a PRoliferation inducing ligand (APRIL), as a new approach to treating IgA nephropathy","authors":"Sheila A Doggrell","doi":"10.1080/14712598.2024.2346111","DOIUrl":"https://doi.org/10.1080/14712598.2024.2346111","url":null,"abstract":"Immunoglobulin A (IgA) nephropathy is a common immune-mediated kidney disease leading to high blood pressure and may progress to kidney failure. None of the present treatments are disease-modifying...","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140625452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancements in biologic therapy in eosinophilic asthma 嗜酸性粒细胞性哮喘生物疗法的进展
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-04-15 DOI: 10.1080/14712598.2024.2342527
Rini Patadia, Thomas B. Casale, John Fowler, Shiven Patel, Juan Carlos Cardet
{"title":"Advancements in biologic therapy in eosinophilic asthma","authors":"Rini Patadia, Thomas B. Casale, John Fowler, Shiven Patel, Juan Carlos Cardet","doi":"10.1080/14712598.2024.2342527","DOIUrl":"https://doi.org/10.1080/14712598.2024.2342527","url":null,"abstract":"Asthma encompasses a spectrum of phenotypes often categorized into two groups- type 2 high (T2 high) and type 2 low (T2 low). T2 high includes atopic and eosinophilic presentations whereas T2 low i...","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140585741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa 对赛库单抗治疗中重度化脓性扁桃体炎的评估
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-04-11 DOI: 10.1080/14712598.2024.2343112
Dimitra Stergianou, Theodora Kanni, Christina Damoulari, Evangelos Giamarellos-Bourboulis
{"title":"An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa","authors":"Dimitra Stergianou, Theodora Kanni, Christina Damoulari, Evangelos Giamarellos-Bourboulis","doi":"10.1080/14712598.2024.2343112","DOIUrl":"https://doi.org/10.1080/14712598.2024.2343112","url":null,"abstract":"Until recently, biologic therapy for hidradenitis suppurativa was limited to anti-tumor necrosis factor (TNF) blockade with adalimumab (ADA). However, not all patients respond to treatment with ADA...","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140585766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 更正。
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-04-04 DOI: 10.1080/14712598.2024.2338643
{"title":"Correction.","authors":"","doi":"10.1080/14712598.2024.2338643","DOIUrl":"https://doi.org/10.1080/14712598.2024.2338643","url":null,"abstract":"","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140745632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial peptides in bone regeneration: mechanism and potential 骨再生中的抗菌肽：机制与潜力
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-04-03 DOI: 10.1080/14712598.2024.2337239
ZhiCheng Wang, XiaoMan Chen, Liang Yan, WenJie Wang, PeiJia Zheng, Atashbahar Mohammadreza, Qi Liu
{"title":"Antimicrobial peptides in bone regeneration: mechanism and potential","authors":"ZhiCheng Wang, XiaoMan Chen, Liang Yan, WenJie Wang, PeiJia Zheng, Atashbahar Mohammadreza, Qi Liu","doi":"10.1080/14712598.2024.2337239","DOIUrl":"https://doi.org/10.1080/14712598.2024.2337239","url":null,"abstract":"Antimicrobial peptides (AMPs) are small-molecule peptides with a unique antimicrobial mechanism. Other notable biological activities of AMPs, including anti-inflammatory, angiogenesis, and bone for...","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140585753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies. 低风险骨髓增生异常综合征中的 Luspatercept：治疗策略的范式转变。
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-04-01 Epub Date: 2024-03-30 DOI: 10.1080/14712598.2024.2336086
Matteo Molica, Marco Rossi
{"title":"Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.","authors":"Matteo Molica, Marco Rossi","doi":"10.1080/14712598.2024.2336086","DOIUrl":"10.1080/14712598.2024.2336086","url":null,"abstract":"<p><strong>Introduction: </strong>In patients with myelodysplastic syndromes (MDS), anemia is prevalent affecting 80%-85% of low-risk (LR-MDS) patients, with 40% eventually requiring red blood cell (RBC) transfusions. Except forlenalidomide, exclusively approved for those with deletion of chromosome 5q,erythropoiesis-stimulating agents (ESAs) are the primary treatment choice for low-risk patients. Those unresponsive to ESAs face limited alternatives, eventually necessitating long-term RBC transfusions, leading to secondary iron overload and adversely affecting quality of life (QoL).</p><p><strong>Area covered: </strong>Luspatercept is a pioneering erythroid maturation agent. It received approval by both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for treating adults experiencing transfusion-dependent anemia associated with LR-MDS or β-thalassemia. Recently, the FDA approved luspatercept as first- line therapy in patients with very low- to intermediate-risk MDS who require RBC transfusions and have not previously received ESAs. This review summarizes the historical impact of luspatercept intreating LR-MDS unresponsive to ESAs and illustrates its potential benefit asfrontline therapy in MDS and its employment in patients with myelofibrosis-induced anemia.</p><p><strong>Expert opinion: </strong>Luspatercept has revolutionized the therapeutic paradigm of LR-MDS, for which there was a limited therapeutic arsenal, especially in the setting of patients who did not respond or fail after ESA treatment.</p>","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140329788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global experience of faricimab in clinical settings - a review. 法尼单抗的全球临床应用经验综述。
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-04-01 Epub Date: 2024-03-29 DOI: 10.1080/14712598.2024.2336087
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Anat Loewenstein, Francesco Bandello, Baruch D Kuppermann
{"title":"Global experience of faricimab in clinical settings - a review.","authors":"Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Anat Loewenstein, Francesco Bandello, Baruch D Kuppermann","doi":"10.1080/14712598.2024.2336087","DOIUrl":"10.1080/14712598.2024.2336087","url":null,"abstract":"<p><strong>Introduction: </strong>Faricimab is a bispecific antibody that acts to reduce neoangiogenesis in exudative retinal vascular disorders. It is approved for use in neovascular age-related macular degeneration and diabetic macular edema. We review the published efficacy and safety of faricimab in clinical settings.</p><p><strong>Areas covered: </strong>A comprehensive literature review was conducted. Based on the 14 published real-world studies, 1127 patients (1204 eyes) were treated with faricimab. The majority of studies (14) included pre-treated patients. Most studies (13) showed central macular thickness improvement. However visual acuity improved in only half of the studies analyzed. Four studies demonstrated an extension of the treatment. Only 4 eyes (0.33%) reported intraocular inflammation and 3 eyes (0.24%) reported retinal pigment epithelial tear.</p><p><strong>Expert opinion: </strong>The clinical experience with faricimab to date has the potential to provide a stable visual outcome with reduced treatment burden in cases that are resistant to other approved anti-VEGF agents. There are no major safety concerns based on this data analysis.</p>","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140318068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAR T cells for solid tumors - developments to watch in 2023. 治疗实体瘤的 CAR T 细胞--2023 年值得关注的发展。
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-04-01 Epub Date: 2024-03-25 DOI: 10.1080/14712598.2024.2334399
Marcel P Trefny, Sebastian Kobold
{"title":"CAR T cells for solid tumors - developments to watch in 2023.","authors":"Marcel P Trefny, Sebastian Kobold","doi":"10.1080/14712598.2024.2334399","DOIUrl":"10.1080/14712598.2024.2334399","url":null,"abstract":"","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revolutionizing the management of patients with atopic dermatitis: practical considerations. 彻底改变特应性皮炎患者的治疗方法：实际考虑因素。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-04-01 Epub Date: 2024-03-24 DOI: 10.1080/14712598.2024.2334380
Filomena Russo, Anna Rita Giampetruzzi, Maria Antonietta Pilla, Ornella De Pità, Elisa Camela
{"title":"Revolutionizing the management of patients with atopic dermatitis: practical considerations.","authors":"Filomena Russo, Anna Rita Giampetruzzi, Maria Antonietta Pilla, Ornella De Pità, Elisa Camela","doi":"10.1080/14712598.2024.2334380","DOIUrl":"10.1080/14712598.2024.2334380","url":null,"abstract":"","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信